Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | GALR3 | O60755 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PRKCA | P17252 | 2/20 | 0.32 |
| ▸ | PGD | P52209 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL27945359 | 0.98 | TSHR (0.37) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| Cadaverine Tartrate SCHEMBL27695422 | 0.90 | PDE4A (0.44) | TSHRPDE4ALMNAPGDALOX15 | |
| SCHEMBL18451403 | 0.85 | LMNA (0.44) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL9539845 | 0.84 | PDE4A (0.40) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL7532569 | 0.84 | TSHR (0.37) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL6142502 | 0.84 | TDP1 (0.46) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL15267779 | 0.82 | TDP1 (0.35) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL7501446 | 0.81 | LMNA (0.35) | TDP1PDE4ALMNAL3MBTL1USP2 | |
| Stearic Acid SCHEMBL5368329 | 0.80 | GPR84 (0.50) | TSHRMAPTTDP1PDE4APRKCA | |
| Dodecanoate SCHEMBL28078379 | 0.80 | GPR84 (0.50) | TSHRMAPTTDP1PDE4APRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 287 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260033491-A1 | FUNGAL SPORE FORMULATIONS INCLUDING CARRIER FLUIDS | BAYER AG (DE) | 2026-02-05 | — | — | US | claimed |
| CN-120202025-A | Compositions for enhancing nucleic acid delivery | 深圳鸿生生物科技有限公司 | 2025-06-24 | — | — | CN | claimed |
| EP-3443034-B1 | COMPOSITION | DELTA OF SWEDEN AB (SE) | 2024-04-10 | — | — | EP | claimed |
| CN-117356562-A | Novel carrier liquid for liquid fungal spore formulations | 拜耳公司 | 2024-01-09 | — | — | CN | claimed |
| US-11795318-B2 | Composition | DELTA OF SWEDEN AB (SE) | 2023-10-24 | — | — | US | claimed |
| CN-113274342-B | Colchicine external composition | 北京天衡军威医药技术开发有限公司 | 2023-06-02 | — | — | CN | claimed |
| CN-115960426-A | Model compound and preparation method and application thereof | 瑞典德尔塔公司 | 2023-04-14 | — | — | CN | claimed |
| CN-115813863-A | Microsphere capable of spontaneously agglomerating and preparation method thereof | 广州因明生物医药科技股份有限公司 | 2023-03-21 | — | — | CN | claimed |
| CN-109312109-B | Composition comprising a fatty acid ester and a fatty acid ester | 瑞典德尔塔公司 | 2022-10-28 | — | — | CN | claimed |
| US-20220007643-A1 | NOVEL CARRIER FLUIDS FOR LIQUID FUNGAL SPORE FORMULATIONS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2022-01-13 | — | — | US | claimed |
| CN-1857247-A | Oxaliplatin emulsion for intravenous injection and its preparing method | DADAOLONGDA BEIJING MEDICINE S (CN) | 2006-11-08 | — | — | CN | claimed |
| CN-1850096-A | Aclarubicin venous emulsion and its preparing method | DADAOLONGDA BEIJING PHARMACEUT (CN) | 2006-10-25 | — | — | CN | claimed |
| CN-1850066-A | Carboplatin venous emulsion and its preparing method | DADOLONGDA BEIJING PHARMACEUTI (CN) | 2006-10-25 | — | — | CN | claimed |
| CN-1241549-C | Amphoteric liposomes and the use thereof | NOVOSON AG (DE) | 2006-02-15 | — | — | CN | claimed |
| EP-1100479-B1 | MEDICINAL PRODUCTS WITH RETARDED PHARMACOLOGICAL ACTIVITY AND METHOD FOR THE PRODUCTION THEREOF | SCHIERHOLZ JOERG DR DR (DE) | 2006-01-11 | — | — | EP | claimed |
| US-6824807-B2 | ACID PRECURSOR, ENZYME FOR HYDROLYZING IT, AND AN ALKALINE CARBONATE; MAJORITY OF CO2 GENERATED COMES FROM REACTION OF ACID GENERATED AND CARBONATE | THE PILLSBURY COMPANY | 2004-11-30 | — | — | US | claimed |
| CN-1492756-A | Amphoteric liposomes and the use thereof | ����ŵķ����Ԫ�������ɷ�����˾ | 2004-04-28 | — | — | CN | claimed |
| US-20030133829-A1 | Process for inactivating pathogens in a biological material | BAXTER HEALTHCARE CORPORATION | 2003-07-17 | — | — | US | claimed |
| WO-2003053477-A1 | PROCESS FOR INACTIVATING PATHOGENS IN A BIOLOGICAL SOLUTION | BAXTER INTERNATIONAL INC. (US) | 2003-07-03 | — | — | WO | claimed |
| US-20030113424-A1 | Chemical leavener system comprising acidulant precursors | THE PILLSBURY COMPANY | 2003-06-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220007643-A1 | NOVEL CARRIER FLUIDS FOR LIQUID FUNGAL SPORE FORMULATIONS | GET3, ERG28, SUCLG1 | TSHR 4772/4885CHRM2 3759/4885CHRM4 4351/4885 |
| US-20260033491-A1 | FUNGAL SPORE FORMULATIONS INCLUDING CARRIER FLUIDS | ERG28, CERT1, MGLL | TSHR 3841/4885CHRM2 1598/4885CHRM4 3000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.